Fast Five Quiz: Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation

Sandeep K. Goyal, MD


March 08, 2022

Kidney function declines over time and therefore periodic monitoring should be performed to assess whether anticoagulant dose modifications may be warranted. Direct oral anticoagulants (DOACs) are noninferior to warfarin among patients with CKD; however, no direct comparisons have been performed to provide sufficient evidence to recommend one particular DOAC over another. The DOAC safety profiles appear to be superior to warfarin, reducing the risk for intracranial hemorrhage. Annual reevaluation of treatment goals with discussion of the benefits and harms of continued anticoagulation therapy should be performed.

Learn more about managing patients with CKD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.